Plus Therapeutics (DE:XMP1)
NASDAQ:XMP1
XMP1 Analyst Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
XMP1 Stock 12 Month Forecast
Average Price Target
€32.71
▲(2795.05% Upside)
| Highest Price Target€55.96 | Average Price Target€32.71 | Lowest Price Target€10.33 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Lake Street
€43.04
Buy
3709.28%
Upside
Reiterated
05/19/26
Maxim Group
€10.33
Buy
814.23%
Upside
Reiterated
05/19/26
Ascendiant
€55.96
Buy
4852.06%
Upside
Reiterated
04/08/26
We are maintaining our 2026 estimates for revenue (grant and CNSide revenue) of $4 million, but adjusting it for EPS to $(3.56) from $(3.22). Focus on RNL (REYOBIQ) for oncology: The company is focused on its clinical stage oncology pipeline. The lead drug is a Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda) (now called REYOBIQ), is being developed for recurrent glioblastoma (GBM) but has expanded to LM (leptomeningeal metastases) which is now the key focus of the company. Glioblastoma is a rare, incurable, and fatal brain cancer with no good treatment options. RNL is currently being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. RNL is infused directly into the brain tumor to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following treatments with surgery, chemotherapy, and radiation.
D. Boral Capital
―
Hold
―
Downgraded
03/31/26
H.C. Wainwright
€21.52
Buy
1804.64%
Upside
Reiterated
03/16/26
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Lake Street
€43.04
Buy
3709.28%
Upside
Reiterated
05/19/26
Maxim Group
€10.33
Buy
814.23%
Upside
Reiterated
05/19/26
Ascendiant
€55.96
Buy
4852.06%
Upside
Reiterated
04/08/26
We are maintaining our 2026 estimates for revenue (grant and CNSide revenue) of $4 million, but adjusting it for EPS to $(3.56) from $(3.22). Focus on RNL (REYOBIQ) for oncology: The company is focused on its clinical stage oncology pipeline. The lead drug is a Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda) (now called REYOBIQ), is being developed for recurrent glioblastoma (GBM) but has expanded to LM (leptomeningeal metastases) which is now the key focus of the company. Glioblastoma is a rare, incurable, and fatal brain cancer with no good treatment options. RNL is currently being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. RNL is infused directly into the brain tumor to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following treatments with surgery, chemotherapy, and radiation.
D. Boral Capital
―
Hold
―
Downgraded
03/31/26
H.C. Wainwright
€21.52
Buy
1804.64%
Upside
Reiterated
03/16/26
Best Analysts Covering Plus Therapeutics
3 Months
Success Rate
3/13 ratings generated profit
Average Return
-12.32%
Copying Edward Woo's trades and holding each position for 3 Months would result in 23.08% of your transactions generating a profit, with an average return of -12.32% per trade.
1 Year
Success Rate
1/13 ratings generated profit
Average Return
-50.70%
Copying Edward Woo's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -50.70% per trade.
2 Years
Success Rate
1/13 ratings generated profit
Average Return
-61.44%
Copying Edward Woo's trades and holding each position for 2 Years would result in 7.69% of your transactions generating a profit, with an average return of -61.44% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
XMP1 Analyst Recommendation Trends
Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
6
8
9
9
6
Buy
0
0
0
0
0
Hold
0
1
1
1
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
9
10
10
6
Each month's total comprises the sum of three months' worth of ratings.
XMP1 Financial Forecast
XMP1 Stock Forecast FAQ
What is DE:XMP1’s average 12-month price target, according to analysts?
Based on analyst ratings, Plus Therapeutics’s 12-month average price target is 32.71.
What is DE:XMP1’s upside potential, based on the analysts’ average price target?
Plus Therapeutics has 2795.05% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Plus Therapeutics a Buy, Sell or Hold?
Plus Therapeutics has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
What is Plus Therapeutics’s share price target?
The average share price target for Plus Therapeutics is 32.71. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €55.96 ,and the lowest forecast is €10.33. The average share price target represents 2795.05% Increase from the current price of €1.13.
The highest analyst share price target is €55.96 ,and the lowest forecast is €10.33. The average share price target represents 2795.05% Increase from the current price of €1.13.
What do analysts say about Plus Therapeutics?
Plus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of Plus Therapeutics?
To buy shares of DE:XMP1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.